News from heptares therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 05, 2017, 03:00 ET Heptares Founder Richard Henderson Receives Nobel Prize in Chemistry 2017 for Pioneering Work in Cryo-EM for Visualising Biological Structures

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), is delighted that one of ...


Aug 31, 2017, 19:15 ET Heptares Enters a New Research and Drug Discovery Collaboration Under its 'Orbit' Initiative with Juntendo University

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces the launch of a new...


Aug 31, 2017, 19:01 ET First Subject Dosed in Phase 1 Clinical Study of Novel Selective MUSCARINIC M4 Agonist in Development to Treat Major Symptoms of Alzheimer's Disease

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that the first...


Jul 13, 2017, 04:00 ET Heptares Hosts Scientific Symposium in Celebration Of 10-year Anniversary

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), hosts a scientific symposium...


Jun 28, 2017, 03:00 ET Heptares Enters a New Research and Drug Discovery Collaboration Under its "Orbit" Initiative With New York University School of Medicine

New programme focused on key GPCR target implicated in aggressive brain cancer Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of...


Jun 20, 2017, 03:00 ET Heptares Plans Relocation to Cambridge, UK

Company to create a state-of-art R&D facility on Granta Park to support growth strategy Heptares Therapeutics ("Heptares"), the leading GPCR medicine ...


May 31, 2017, 13:10 ET Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist

New findings highlight complexity of receptor interactions and provide crucial insights for development of peptide and small molecule therapeutics -...


May 18, 2017, 03:00 ET Heptares' Co-Founder and Chief Scientific Officer, Fiona Marshall, Receives 2017 John Daly Lecture Award in Recognition of Her Outstanding Contribution to GPCR Drug Discovery

Heptares Therapeutics ("Heptares"), the leading GPCR medicine design and development company and wholly-owned subsidiary of Sosei Group Corporation...


May 18, 2017, 03:00 ET Heptares to Receive US$5 Million Milestone Payment From Teva

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), has been notified by its ...


Apr 27, 2017, 02:30 ET Heptares Collaboration With AstraZeneca Yields New Insights to Advance Drug Discovery in Pain, Cancer and Inflammation

Novel mechanisms of action highlighted from resolved structures of PAR2 bound to antagonist molecules - research published in Nature Heptares...


Apr 05, 2017, 02:35 ET Heptares To Receive US$12 Million Milestone Payment From AstraZeneca

- AZD4635 (HTL-1071), a novel adenosine A2A receptor antagonist, reverses adenosine-mediated T-cell suppression and enhances anti-tumour immunity -...


Mar 13, 2017, 03:05 ET Heptares Therapeutics Enters Agreement With Daiichi Sankyo to Discover and Develop Novel, Small-molecules for the Treatment of Pain

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announces that it has...


Jan 31, 2017, 03:21 ET Heptares Enters a New Research Collaboration Under Its 'Orbit' Initiative With the University of Cambridge

New Programme Focused on Apelin Receptor in Cardiovascular Diseases Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group...


Dec 08, 2016, 03:00 ET Heptares Scientists Solve Structure of CCR9 Chemokine Receptor Offering Unique Opportunity to Apply Structure-Based Design Across Chemokine Receptor Family

Chemokine receptor family plays key role across multiple disease areas and represents an important target for drug discovery and development...


Nov 29, 2016, 07:15 ET Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has signed a share ...


Jul 06, 2016, 02:42 ET Initiation of Phase 1 Clinical Study With Novel Immuno-oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has been notified...


Jun 29, 2016, 04:00 ET Heptares and Leadxpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and leadXpro AG ("leadXpro"), a ...


Apr 28, 2016, 05:05 ET Heptares Chief Scientific Officer and Co-founder - Dr Fiona Marshall - Elected as a Fellow of the Academy of Medical Sciences

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that Dr Fiona...


Apr 25, 2016, 11:05 ET Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-based Design for Metabolic Disease

First structure of GLP-1 receptor in active state resolved Novel allosteric binding site in glucagon receptor identified - published in Nature...


Apr 18, 2016, 03:00 ET Heptares and Kymab Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and Kymab Limited, a leading...


Apr 04, 2016, 07:39 ET Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has partnered with ...


Feb 10, 2016, 01:30 ET Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Demonstrates changes in brain activity, therapeutic window and M1 receptor selectivity Heptares Therapeutics ("Heptares"), the wholly-owned...


Feb 02, 2016, 04:00 ET Heptares Launches "Orbit" Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS)

First collaboration initiated with Imperial College London Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation ...


Nov 30, 2015, 05:00 ET Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

Heptares Therapeutics ("Heptares"), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of...


Sep 28, 2015, 03:00 ET Heptares Awarded $5.5 Million Research & Development Grant From the US National Institute on Drug Abuse (NIDA)

Project to develop first-in-class Orexin-1 receptor antagonist for the treatment of cocaine addiction and dependence. Heptares Therapeutics...